环状聚四氟乙烯人工血管重建肝静脉流出道在右半肝活体肝移植中的应用价值

Application value of hepatic vein outflow tract reconstruction with ringed polytetrafluoroe-thylene vascular in right lobe living donor liver transplantation

  • 摘要:
    目的 探讨环状聚四氟乙烯人工血管重建肝静脉流出道在右半肝活体肝移植中的应用价值。
    方法 采用回顾性描述性研究方法。收集2015年6月至2018年8月南京大学医学院附属鼓楼医院收治的4例和南京医科大学第一附属医院收治的17例行右半肝活体肝移植供者和对应21例受者的临床病理资料;21例供者中,男10例,女11例;中位年龄为46岁,年龄范围为35~57岁;中位体质量为64 kg,体质量范围为56~72 kg。21例受者中,男16例,女5例;中位年龄为42岁,年龄范围为21~68岁;中位体质量为63 kg,体质量范围为47~77 kg。观察指标:(1)手术及术后情况。(2)随访情况。采用门诊或电话方式进行随访,了解受者术后移植肝功能、肝癌复发、人工血管并发症、人工血管通畅性、生存等情况。随访时间截至2020年8月。受者需终生定期随访。正态分布的计量资料以x±s表示,偏态分布的计量资料以M(范围)表示。计数资料以绝对数或百分比表示。采用Kaplan⁃Meier 法计算通畅率和生存率并绘制通畅率曲线和生存曲线。
    结果 (1)手术及术后情况:21例供者手术时间为(367±72)min,供肝质量为(557±68)g,供肝质量与受者体质量比为0.89%±0.16%,住院时间为(10±2)d。21例供者术后未出现需再次手术或有创处理并发症,1例轻度胆瘘,术后留置腹腔引流管1周拔除。21例受者均顺利完成经典原位肝移植。供肝静脉流出道重建时间为(24±4)min,供肝植入时间为(326±66)min,无肝期为(42±6)min。重建肝中静脉V5 18支,直径为(6.1±1.3)mm,V8 15支,直径为(7.2±1.2)mm,肝右后下静脉10支,直径为(6.3±1.3)mm。受者术后入住重症监护室时间为(1.5±0.9)d,总住院时间为(22.6±6.7)d。21例受者中,10例术后发生并发症,其中5例术后1周发生肝功能异常(丙氨酸氨基转移酶、天冬氨酸氨基转移酶均>1 000 IU/L,胆红素轻度升高),同时伴腹腔积液增加;行增强CT检查结果示供肝右前叶淤血,肝中静脉V5或V8分支血栓形成,经保肝、抗凝、输注白蛋白等对症治疗后肝功能均恢复正常,腹腔积液减少。2例术后1个月下腔静脉血栓形成,反复出现胸腔积液,行腔静脉造影检查,考虑人工血管血栓形成(其中1例腔静脉旁侧支循环形成,予以球囊扩张并置入腔静脉支架),术后继续口服华法林抗凝治疗后恢复正常。1例胆瘘(腹腔引流液培养出肺炎克雷伯杆菌),1例腹腔感染,1例肺部感染,均经抗感染对症治疗后恢复正常。21例受者无严重并发症和围术期死亡。(2)随访情况:21例受者均获得随访,随访时间为10~57个月,中位随访时间为38个月。21例受者术后6个月均未出现移植肝无功能,其中2例肝癌复发。术后2年6例受者死亡(肝癌复发3例、急性大出血2例、肝衰竭1例),无因人工血管引起的严重并发症死亡。21例受者术后1个月、3个月、6个月、1年、2年肝静脉流出道通畅率分别为88.4%、88.4%、82.4%、68.0%、42.1%。21例受者术后6个月、1年、2年总体生存率分别为100.0%、94.4%、71.4%。
    结论 环状聚四氟乙烯人工血管重建肝静脉流出道应用于右半肝活体肝移植安全、可行。

     

    Abstract:
    Objective To investigate the application value of hepatic vein outflow tract reconstruction with ringed polytetrafluoroethylene vascular in right lobe living donor liver trans-plantation.
    Methods The retrospective and descriptive study was conducted. The clinicopatho-logical data of 4 donors and 4 recipients undergoing right lobe living donor liver transplantation in Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School and 17 donors and 17 recipients undergoing right lobe living donor liver transplantation in the First Affiliated Hospital with Nanjing Medical University from June 2015 to August 2018 were collected. Of 21 donors, there were 10 males and 11 females, aged from 35 to 57 years, with a median age of 46 years. The median body mass of 21 donors were 64 kg, with a range from 56 to 72 kg. Of 21 recipients, there were 16 males and 5 females, aged from 21 to 68 years, with a median age of 42 years. The median body mass of 21 recipients were 63 kg, with a range from 47 to 77 kg. Observation indicators: (1) surgical and postoperative situations; (2) follow-up. Follow-up was conducted by outpatient examination or telephone interview to detect graft function, tumor recurrence, vascular graft complications, patency of vascular graft and survival of recipients up to August 2020. All recipients will be followed up for all their lives. Measurement data with normal distribution were represented as Mean±SD and measurement data with skewed distribution were represented as M (range). Count data were represented as absolute numbers or percentages. The Kaplan-Meier method was used to calculate patency rates of hepatic vein outflow tract and survival rates to draw patency curve and survival curve.
    Results (1) Surgical and postoperative situations: the operation time, the weight of donor graft, graft to recipient weight ratio and duration of hospital stay of 21 donors were (367±72)minutes, (557±68)g, 0.89%±0.16% and (10+2)days, respectively. No major complication requiring reoperation or intervention occurred in any of the 21 donors. One donor undergoing mild bile leakage preserved peritoneal drainage for one week. All 21 recipients underwent classic orthotopic liver transplantation successfully. The time of hepatic vein outflow tract reconstruction in donor graft, operation time and time of anhepatic phase of 21 recipients were (24±4)minutes, (326±66)minutes and (42±6)minutes, respectively. The number of reconstructed middle hepatic vein in hepatic segment 5 and 8 were 18 and 15, with the diameter of (6.1±1.3)mm and (7.2±1.2)mm, respectively. The number of reconstructed inferior right hepatic vein were 10, with the diameter of (6.3±1.3)mm. The postoperative treatment time at intensive care unit and duration of hospital stay of 21 recipients were (1.5±0.9)days and (22.6±6.7)days, respectively. Ten of 21 recipients underwent postoperative complications. Five recipients underwent graft dysfunction including the level of alanine aminotransferase and aspartate aminotransferase >1 000 IU/L and the level of bilirubin slightly increasing, combined with increased ascites. Enhanced computed tomography scan showed congestion in the right anterior of graft and thrombosis in the middle hepatic vein of hepatic segment 5 and segment 8. All 5 recipients undergoing graft dysfunction recovered with normal liver function and ascites decreasing after symptomatic treatment including liver protection therapy, anticoagulation and albumin infusion. Two recipients underwent inferior vena cava thrombosis and intractable pleural effusion one month after operation. Vena cava venography examination showed thrombosis in the graft vascular. Of the 2 recipients, one case with collateral circulation formation recovered undergoing balloon dilatation and stent placement combined with anticoagulation therapy of warfarin. The other one case recovered after anticoagulation therapy of warfarin. One recipient undergoing bile leakage and abdominal infection with klebsiella pneumoniae recovered after symptomatic treatment. Two recipients undergoing abdominal infection or pulmonary infection recovered after symptomatic treatment. There was no serious complication or death during perioperative period. (2) Follow-up: all 21 recipients were followed up for 10 to 57 months, with a median follow-up time of 38 months. During the follow-up, no recipient underwent graft dysfunction and 2 recipients had tumor recurrence at postoperative 6 months. Six of the 21 recipients died within 2 years after operation including 3 cases dying of tumor recurrence, 2 cases dying of acute hemorrhage and 1 case dying of liver failure. There was no death caused by vascular graft complica-tions. The postoperative 1, 3, 6-month, and 1-year and 2-year potency rates of hepatic vein outflow tract in 21 recipients were 88.4%, 88.4%, 82.4%, 68.0% and 42.1%, respectively. The 6-month, 1-year and 2-year overall survival rates in 21 recipients were 100%, 94.4%, 71.4%, respectively.
    Conclusion Application of hepatic vein outflow tract reconstruction with ringed polytetrafluoroethylene vascular in right lobe living donor liver transplantation is safe and feasible.

     

/

返回文章
返回